Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCleu mediated T-cell activation and on-target/off-tumor toxici... by Hazal Aslan Rejeski, Hazal Aslan Rejeski, Anne Hartz, Anne Hartz, Elias Rackl, Elias Rackl, Lin Li, Lin Li, Christoph Schwepcke, Christoph Schwepcke, Kai Rejeski, Kai Rejeski, Christoph Schmid, Christoph Schmid, Andreas Rank, Andreas Rank, Jörg Schmohl, Doris Kraemer, Peter Bojko, Helga Maria Schmetzer, Helga Maria Schmetzer

“…Overall, DCleu-based immunotherapy represents a promising treatment strategy for AML patients.…”
Get full text

What Makes Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells Superior Immunomodulators When Compared to Bone Marrow Derived Mesenchymal Stromal Cells? by R. N. Bárcia, J. M. Santos, M. Filipe, M. Teixeira, J. P. Martins, J. Almeida, A. Água-Doce, S. C. P. Almeida, A. Varela, S. Pohl, K. E. J. Dittmar, S. Calado, S. I. Simões, M. M. Gaspar, M. E. M. Cruz, W. Lindenmaier, L. Graça, H. Cruz, P. E. Cruz

“…MSCs derived from the umbilical cord tissue, termed UCX, were investigated for their immunomodulatory properties and compared to bone marrow-derived MSCs (BM-MSCs), the gold-standard in immunotherapy. Immunogenicity and immunosuppression were assessed by mixed lymphocyte reactions, suppression of lymphocyte proliferation and induction of regulatory T cells. …”
Get full text

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review... by Huimin Zhao, Shanshan Huang, Jianyu Wu, Yanlan Lu, Yue Zou, Haijian Zeng, Chunlan Li, Jin Wang, Xiaochen Zhang, Xiaochen Zhang, Siliang Duan, Siliang Duan, Weiming Liang

“…Further randomized controlled trials with prolonged follow-up periods are necessary to validate these results, particularly focusing on efficacy in patients with differing PD-L1 expression levels, to improve the stratified implementation of immunotherapy.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?…”
Get full text

Incidence of type 2 diabetes and metabolic syndrome by Occupation – 10-Year follow-up of the Gutenberg Health Study by Juliane Bauer, Janice Hegewald, Karin Rossnagel, Sylvia Jankowiak, Michaela Prigge, Julian Chalabi, Matthias Nübling, Alice Freiberg, Merle Riechmann-Wolf, Pavel Dietz, Philipp S. Wild, Thomas Koeck, Manfred E. Beutel, Norbert Pfeiffer, Karl J. Lackner, Thomas Münzel, Konstantin Strauch, Philipp Lurz, Oliver Tüscher, Julia Weinmann-Menke, Stavros Konstantinides, Andreas Seidler

Get full text

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III... by Roger Owen, John Jones, David Meads, David A Cairns, Christopher Parrish, Gordon Cook, Neil Rabin, Matthew Jenner, Martin Kaiser, Kevin Boyd, Graham Jackson, Catherine Olivier, Amy Beth Coulson, Kara-Louise Royle, Charlotte Pawlyn, Anna Hockaday, Jennifer Bird, Stella Bowcock, Ruth de Tute, Hayley Gardner, Bryony Dawkins, Rowena Henderson, Phillip Best, Bhuvan Kishore, Mark Drayson

Get full text

Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy by Yishen Tian, Jingxuan Li, Na Yang, Yang Zhao, Jiancao Zuo, Hang Xiong, Yiwen Pan, Li Xiao, Min Su, Feng Han, Zhixu He, Rong Hu

“…This research provided a novel platform for the synergistic cooperation of various methods in tumor immunotherapy, holding broad application prospects.…”
Get full text

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer by Lei Wang, Yafei You, Wenzhuo He, Yu Hou, Lan Li, Li Wang, Chang Jiang, Jiahong Yi, Yaoxiong Xia, Liangping Xia

“…Efficacy of pralsetinib was decreased in patients previously treated with PBC, immunotherapy, or MKIs.…”
Get full text

Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma by Zhong Zheng, Jian-Biao Wang, Rui Sun, Nan Wang, Xiang-Qin Weng, Tian-Yuan Xu, Di Fu, Yan Feng, Peng-Peng Xu, Shu Cheng, Li Wang, Yan Zhao, Bin Qu, Chuan-Xin Huang, Wei-Li Zhao

“…We conducted the first trial of immunotherapy rituximab plus lenalidomide in newly diagnosed FL in China (NCT03715309). …”
Get full text

Construction of feature selection and efficacy prediction model for transformation therapy of locally advanced pancreatic cancer based on CT, 18F-FDG PET/CT, DNA mutation, and CA19... by Liang Qi, Xiang Li, Jiayao Ni, Yali Du, Qing Gu, Baorui Liu, Jian He, Juan Du

“…Abstract Background Immunotherapy and radiotherapy play crucial roles in the transformation therapy of locally advanced pancreatic cancer; however, the exploration of effective predictive biomarkers has been unsatisfactory. …”
Get full text

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target by Cèlia Dobaño-López, Juan García Valero, Ferran Araujo-Ayala, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Fabian Arenas, Marta Grau, Cristina López, Irene López-Oreja, Neus Serrat, Ares Martínez-Farran, Lluís Hernández, Heribert Playa-Albinyana, Rubén Giménez, Silvia Beà, Elías Campo, Jean-Michel Lagarde, Armando López-Guillermo, Laura Magnano, Dolors Colomer, Christine Bezombes, Patricia Pérez-Galán

“…Moreover, this system is suitable for chemo and immunotherapy testing, recapitulating results obtained in the clinic. …”
Get full text

Cholesterol Targeted Catalytic Hydrogel Fueled by Tumor Debris can Enhance Microwave Ablation Therapy and Anti‐Tumor Immune Response by Lin Shen, Zhijuan Yang, Yi Zhong, Yanran Bi, Junchao Yu, Qinwei Lu, Yanping Su, Xiaoxiao Chen, Zhongwei Zhao, Gaofeng Shu, Minjiang Chen, Liang Cheng, Liangzhu Feng, Chenying Lu, Zhuang Liu, Jiansong Ji

“…Combined with anti‐PD‐L1 immunotherapy, this strategy inhibited primary tumor growth and distant metastases, without side effects on adjacent tissues. …”
Get full text

Recurrent adenoid cystic carcinoma of the left upper palate accompanied by massive maxillary hemorrhage: a case report and literature review by ZHANG Wangru, CHEN Yuanyuan, LI Zhiping, MENG Jian

“…An individualized treatment plan was developed under MDT, incorporating postoperative radiotherapy, targeted therapies, and immunotherapy to manage the tumor. Results Through the MDT model, the patient successfully achieved emergency hemostasis, and normal vital signs were restored. …”
Get full text

Hydrogen‐Generating Magnesium Alloy Seed Strand Sensitizes Solid Tumors to Iodine‐125 Brachytherapy by Pan Hu, Letao Lin, Guanyu Chen, Dengyao Liu, Huanqing Guo, Meigui Xiao, Zhihui Zhong, Guang Yang, Bingchen Xu, Dongcun Huang, Sheng Peng, Yong Li, Yanling Zhang, Tao Huang, Fujun Zhang

“…Hydrogen gas has anticancer properties and can enhance the efficacy of immunotherapy. However, its role in radiotherapy sensitization has rarely been reported. …”
Get full text

VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment by Cheng Cheng, Qingrui Zha, Linmao Sun, Tianming Cui, Xinyu Guo, Changjian Xing, Zhengxiang Chen, Changyong Ji, Shuhang Liang, Shengwei Tao, Junhui Chu, Chenghui Wu, Qi Chu, Xuetian Gu, Ning Zhang, Yumin Fu, Shumin Deng, Yitong Zhu, Jiabei Wang, Yao Liu, Lianxin Liu

“…These findings highlight a previously unrecognized mechanism involving VCP and G3P in suppressing T-cell-mediated immunity in the TME, positioning VCP as a promising upstream target for enhancing immunotherapy in HCC.…”
Get full text

Disrupting EDEM3‐induced M2‐like macrophage trafficking by glucose restriction overcomes resistance to PD‐1/PD‐L1 blockade by Shaoyong Peng, Minshan Wu, Qian Yan, Gaopo Xu, Yumo Xie, Guannan Tang, Jinxin Lin, Zixu Yuan, Xiaoxia Liang, Ze Yuan, Jingrong Weng, Liangliang Bai, Xiaolin Wang, Huichuan Yu, Meijin Huang, Yanxin Luo, Xiaoxia Liu

“…Abstract Background Immunotherapy is beneficial for some colorectal cancer (CRC) patients, but immunosuppressive networks limit its effectiveness. …”
Get full text

Dynamic Challenges of Active Tuberculosis: Prevalence and Risk Factors of Co-Infection in Clinical and Microbiological Characteristics at King Abdulaziz University Hospital, Jeddah... by Mokhtar JA, Attallah DM, Jiman-Fatani AA, Al-Rabia MW, Alqarni MA, Saleh BH, Amboon MM, Altorki TA, Alkuwaity KK, Abujamel T, Kaki R, Albarakati TN, Daghistani H, Ismail MA, Alharbi O, Abu ITM, Alfadil A, Ibrahem K, Mufrrih M, Sait AM

“…Jawahir A Mokhtar,1– 3 Dalya M Attallah,2 Asif Ahmad Jiman-Fatani,1,2 Mohammed W Al-Rabia,1 Mona Abdulrahman Alqarni,1 Bandar Hasan Saleh,1,2 Maysaa Mohammed Amboon,4 Tarfa A Altorki,3,4 Khalil K Alkuwaity,3,4 Turki Abujamel,3,4 Reham Kaki,5,6 Taghreed Nassir Albarakati,7 Hussam Daghistani,8,9 Mazen A Ismail,10 Ohood Alharbi,11 Ibrahim Ismail Mohammed Abu,12 Abdelbagi Alfadil,1,13 Karem Ibrahem,1,2 Mohammed Mufrrih,4,14 Ahmad M Sait4,9 1Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 2Department of Clinical Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah, 21589, Saudi Arabia; 3Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 4Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 5Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 6Department of Infectious Disease & Infection Control and Environmental Health, King Abdulaziz University Hospital, Jeddah, Saudi Arabia; 7Microbiology Unite in King Fahd General hospital Jeddah (KFHJ), Jeddah, Saudi Arabia; 8Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University Jeddah, Jeddah, 21589, Saudi Arabia; 9Regenerative Medicine Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 10Department of Medical Education, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 11Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia; 12Department of Community Medicine, Faculty of medicine, King Abdulaziz University, Jedda, 21589, Saudi Arabia; 13Centre of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia; 14Special Infectious Agents Unit BSL-3, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi ArabiaCorrespondence: Karem Ibrahem, Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, P.O. …”
Get full text

γδ T Cells’ Role in Donor-Specific Antibody Generation: Insights From Transplant Recipients and Experimental Models by Xavier Charmetant, Xavier Charmetant, Xavier Charmetant, Guillaume Rigault, Chien-Chia Chen, Hannah Kaminski, Hannah Kaminski, Jonathan Visentin, Jonathan Visentin, Benjamin Taton, Gabriel Marseres, Virginie Mathias, Alice Koenig, Alice Koenig, Alice Koenig, Thomas Barba, Thomas Barba, Thomas Barba, Pierre Merville, Pierre Merville, Stéphanie Graff-Dubois, Emmanuel Morelon, Emmanuel Morelon, Emmanuel Morelon, Julie Déchanet-Merville, Valérie Dubois, Jean-Paul Duong van Huyen, Lionel Couzi, Lionel Couzi, Olivier Thaunat, Olivier Thaunat, Olivier Thaunat

Get full text

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma by Seema Chugh, Jean C. Tien, Jennifer Hon, Carson Kenum, Rahul Mannan, Yunhui Cheng, Chi Chiang Li, Zainab I. Taher, Andrew D. Delekta, Pushpinder Singh Bawa, Ingrid J. Apel, Stephanie J. Miner, Xuhong Cao, Rohit Mehra, Saravana M. Dhanasekaran, Yuanyuan Qiao, Rajen Mody, Arul M. Chinnaiyan

“…Standard therapy involves highly toxic chemotherapy, surgery, radiation, and immunotherapy, and less toxic, more specific targeted therapies are urgently needed. …”
Get full text

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer by Lorenzo Castagnoli, Alma Franceschini, Valeria Cancila, Matteo Dugo, Martina Bigliardi, Claudia Chiodoni, Paolo Toneguzzo, Viola Regondi, Paola A. Corsetto, Filippo Pietrantonio, Serena Mazzucchelli, Fabio Corsi, Antonio Belfiore, Antonio Vingiani, Giancarlo Pruneri, Francesca Ligorio, Mario P. Colombo, Elda Tagliabue, Claudio Tripodo, Claudio Vernieri, Tiziana Triulzi, Serenella M. Pupa

Get full text

Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma by Tingting Zhang, Tianyuan Ren, Zheng Song, Jing Zhao, Lei Jiao, Zhenzhen Zhang, Jin He, Xianming Liu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

“…Tim-3 is a promising target for antitumor immunotherapy. A number of clinical trials are evaluating the efficacy of anti-Tim-3 therapies as a single agent or combinations in solid tumors and haematologic malignancies. …”
Get full text